2,4,5-Trifluorophenylacetic Acid CAS 209995-38-0 Purity ≥99.5% (GC) Sitagliptin Phosphate Monohydrate Intermediate

Short Description:

Chemical Name: 2,4,5-Trifluorophenylacetic Acid

CAS: 209995-38-0

Purity: ≥99.5% (GC)

Appearance: White to Off-White Powder

Intermediate of Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9) for the treatment of type 2 diabetes

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Supply Sitagliptin Phosphate Monohydrate Related Intermediates:
Sitagliptin API CAS 486460-32-6
Sitagliptin Phosphate Monohydrate API CAS 654671-77-9
2,4,5-Trifluorophenylacetic Acid CAS 209995-38-0
Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid CAS 486460-00-8
Sitagliptin Triazole Hydrochloride CAS 762240-92-6
Sitagliptin Phosphate Monohydrate Intermediate CAS 486460-21-3

Chemical Properties:

Chemical Name	2,4,5-Trifluorophenylacetic Acid
CAS Number	209995-38-0
CAT Number	RF-PI1191
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C8H5F3O2
Molecular Weight	190.12
Melting Point	121.0 to 125.0℃
Solubility	Soluble in Methanol
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Off-White Powder
Purity / Analysis Method	≥99.5% (GC)
Moisture (K.F)	≤0.50%
Residue on Igniton	≤0.50%
Total Impurities	≤0.50%
Test Standard	Enterprise Standard
Usage	Intermediate of Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

Application:

2,4,5-Trifluorophenylacetic Acid (CAS: 209995-38-0) is an intermediate of Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9). Sitagliptin Phosphate (STG) is used to treat DM type 2 because it improves glycemic control by increasing the levels of active incretin hormones, GLP-1 (peptide-1) and GIP (glucose-dependent insulinotropic peptide). The activation of these incretins in β-pancreatic cells causes increased levels of cyclic adenosine monophosphate (cAMP) and intracellular calcium, with subsequent glucose-dependent insulin secretion (2). This hypoglycemic drug belongs to a new class called dipeptidyl peptidase IV inhibitors. STG was approved by the FDA in 2006.